May 31, 2016 8:50 AM ET

Biotechnology

Company Overview of HealthLinx Limited

Company Overview

As of March 12, 2015, HealthLinx Limited was acquired by Manalto Limited, in a reverse merger transaction. HealthLinx Limited engages in the identification and development of novel, non-invasive, serum, and plasma based multi marker diagnostics. It primarily develops Ovplex, an ovarian cancer diagnostic; and IgY. The company is based in Melbourne, Australia.

50 Queen Street

Level 6

Melbourne, VIC 3000

Australia

Phone:

61 3 8692 9000

Key Executives for HealthLinx Limited

HealthLinx Limited does not have any Key Executives recorded.

HealthLinx Limited Key Developments

HealthLinx Limited, Special/Extraordinary Shareholders Meeting, Feb 23, 2015

HealthLinx Limited, Special/Extraordinary Shareholders Meeting, Feb 23, 2015.

HealthLinx Limited, Annual General Meeting, Jan 12, 2015

HealthLinx Limited, Annual General Meeting, Jan 12, 2015., at 11:00 AUS Eastern Standard Time. Location: The offices of Quinert Rodda & Associates Pty Ltd, Suite 1. Agenda: To consider the Annual Financial Statements of the Company for the financial year ended 30 June 2014 together with the declaration of the Directors, the Directors' Report, the Remuneration Report and the Auditor's Report; to consider the adoption of remuneration report; to consider the election of director ­Mr. Timothy Chapman; to consider the re-election of director ­Mr. Michael Quinert; to consider the approval for disposal of main undertaking; to consider the approval of placement facility; and to consider the ratification of prior issue.

Healthlinx Limited Reports Audited Consolidated Earnings Results for the Year Ended June 30, 2014

HealthLinx Limited reported audited consolidated earnings results for the year ended June 30, 2014. For the period, the company reported revenue of AUD 7,192 against AUD 34,721 for the same period last year. Total revenue and other income was AUD 64,734 against AUD 50,493 for the same period last year. Loss before income tax was AUD 363,677 against AUD 4,365,297 for the same period last year. Net loss was AUD 270,682 or 0.0219 cents per basic and diluted share against AUD 3,952,613 or 0.006 cents per basic and diluted share for the same period last year. Net cash used in operating activities was AUD 353,525 against AUD 661,153 for the same period last year.

Similar Private Companies By Industry

Company Name Region
AbRegen Pty Ltd. Asia
AdAlta Pty Ltd. Asia
Advanced Wound Care Pty Ltd. Asia
Agriliance Pty Ltd. Asia
AION Diagnostics Limited Asia

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact HealthLinx Limited, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.